Syros to Present at Upcoming Investor Conferences in September

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will present at two investor conferences in September 2021, enhancing visibility for the company’s innovative gene-control medicines. The presentations are scheduled for the H.C. Wainwright Annual Global Investment Conference on September 13 at 7:00 a.m. ET, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 2:05 p.m. ET. Webcasts will be available on the Syros website, with archived recordings accessible for 30 days.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at two upcoming investor conferences in September. Management will also be available for one-on-one meetings.

H.C Wainwright 23^rd Annual Global Investment Conference
Date: Monday, September 13
Time: A pre-recorded presentation will be made available beginning at 7:00 a.m. ET.

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Wednesday, September 22
Time: 2:05 p.m. ET

To access the webcasts and subsequent archived recording of each presentation, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005049/en/

Media Contact:

Naomi Aoki

Syros Pharmaceuticals

617-283-4298

naoki@syros.com

Investor Contact:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

When will Syros Pharmaceuticals present at the H.C. Wainwright Conference?

Syros Pharmaceuticals will present on September 13, 2021, at 7:00 a.m. ET.

What time will the Syros Pharmaceuticals presentation at the Oppenheimer Summit take place?

The presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit will occur on September 22, 2021, at 2:05 p.m. ET.

Where can I access the webcasts of Syros Pharmaceuticals' presentations?

Webcasts can be accessed on the Syros Pharmaceuticals website under the Investors & Media section.

What is the focus of Syros Pharmaceuticals' drug development?

Syros Pharmaceuticals focuses on developing medicines that control gene expression, particularly for patients with difficult-to-treat diseases.

What are some key products in Syros Pharmaceuticals' pipeline?

Key products include tamibarotene, SY-2101, and SY-5609, targeting various hematological and solid tumors.